{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:37:03Z","timestamp":1793900223364,"version":"4.8.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Updated guidelines on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were released in 2021 by the American College of Rheumatology jointly with the Vasculitis Foundation and, subsequently, in 2022 by the European Alliance of Associations for Rheumatology. In addition, in 2021, the Kidney Disease: Improving Global Outcomes had released updated recommendations on the treatment of AAV with glomerulonephritis (AAV-GN). Kidney involvement is particularly relevant in microscopic polyangiitis and granulomatosis with polyangiitis, but is less frequent in eosinophilic granulomatosis with polyangiitis. The management of AAV-GN has been a focus for drug development and change over the past 10 years. Avoidance of progression to end-stage kidney disease (ESKD) or kidney failure is one of the main unmet needs in the management of AAV, with ESKD having a major impact on morbidity, health costs and mortality risk. Relevant changes in AAV-GN management are related to remission-induction treatment of patients with severe kidney disease, the use of glucocorticoids and avacopan, and remission-maintenance treatment. All the documents provide guidance in accordance with the evidence-based standard of care available at the time of their release. With our work we aim to (i) show the progress made and identify the differences between guidelines and recommendations, (ii) discuss the supporting rationale for those, and (iii) identify gaps in knowledge that could benefit from additional research and should be revised in subsequent updates.<\/jats:p>","DOI":"10.1093\/ndt\/gfad090","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T04:57:16Z","timestamp":1683781036000},"page":"2637-2651","source":"Crossref","is-referenced-by-count":35,"title":["Management of antineutrophil cytoplasmic antibody\u2013associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines\/recommendations"],"prefix":"10.1093","volume":"38","author":[{"given":"Marta","family":"Casal Moura","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science , Rochester, MN , USA"},{"name":"Faculdade de Medicina da Universidade do Porto, Departamento de Biomedicina , Porto , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Gauckler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck , Innsbruck , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[{"name":"Department of Health, Medicine and Caring Sciences, Link\u00f6ping University , Link\u00f6ping , Sweden"},{"name":"Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema M","family":"Fernandez-Juarez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario La Paz , IdiPAZ, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Division of Nephrology, RWTH Aachen University Hospital , Aachen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Limassol General Hospital , SHSO , Cyprus ; , Nicosia , Cyprus"},{"name":"Medical School, University of Nicosia , SHSO , Cyprus ; , Nicosia , Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Goumenos","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, Patras University Hospital , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Segelmark","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Clinical Sciences Lund, Lund University and Skane University Hospital , Lund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kultigin","family":"Turkmen","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University , Konya , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van Kooten","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tesar","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine and General University Hospital, Charles University , Prague , Czechia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore , MD, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C","family":"Fervenza","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R W","family":"Jayne","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate I","family":"Stevens","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Transplantation, Queen Elizabeth University Hospital , Glasgow , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2023103100561364700_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023103100561364700_bib2","doi-asserted-by":"crossref","first-page":"e000435","DOI":"10.1136\/rmdopen-2017-000435","article-title":"Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis","volume":"3","author":"Heijl","year":"2017","journal-title":"RMD Open"},{"key":"2023103100561364700_bib3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2007.071936","article-title":"Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force","volume":"67","author":"Mukhtyar","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2023103100561364700_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"2023103100561364700_bib5","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.40313","article-title":"The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: a twenty-year US population-based study","volume":"69","author":"Berti","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023103100561364700_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"2023103100561364700_bib7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1046\/j.1523-1755.2003.00843.x","article-title":"Rapidly progressive crescentic glomerulonephritis","volume":"63","author":"Jennette","year":"2003","journal-title":"Kidney Int"},{"key":"2023103100561364700_bib8","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"de Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103100561364700_bib9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","article-title":"Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2023103100561364700_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.semarthrit.2012.09.005","article-title":"Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center","volume":"42","author":"Li","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2023103100561364700_bib11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103100561364700_bib12","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/art.39614","article-title":"Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease","volume":"68","author":"Rhee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023103100561364700_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.7326\/M19-1564","article-title":"Trends in antineutrophil cytoplasmic autoantibody-associated vasculitis-related mortality in the United States, 1999 to 2017","volume":"172","author":"Steinberg","year":"2020","journal-title":"Ann Intern Med"},{"key":"2023103100561364700_bib14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int"},{"key":"2023103100561364700_bib15","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023103100561364700_bib16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2023103100561364700_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2023103100561364700_bib18","doi-asserted-by":"crossref","first-page":"ard\u20132022\u2013223764","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2023103100561364700_bib19","first-page":"1","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2023103100561364700_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"2023103100561364700_bib21","first-page":"S1","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"100","year":"2021","journal-title":"Kidney Int Suppl"},{"key":"2023103100561364700_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2023103100561364700_bib23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2023103100561364700_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2023103100561364700_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000431336","article-title":"Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab","volume":"41","author":"Shah","year":"2015","journal-title":"Am J Nephrol"},{"key":"2023103100561364700_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","article-title":"Rituximab for treatment of severe renal disease in ANCA associated vasculitis","volume":"29","author":"Geetha","year":"2016","journal-title":"J Nephrol"},{"key":"2023103100561364700_bib27","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe renal disease","volume":"31","author":"Casal Moura","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2023103100561364700_bib28","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/ndt\/gfr127","article-title":"Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis","volume":"26","author":"Mansfield","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100561364700_bib29","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Gulati","year":"2021","journal-title":"Kidney Int"},{"key":"2023103100561364700_bib30","first-page":"260","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023103100561364700_bib31","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2023103100561364700_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100561364700_bib33","year":"2022"},{"key":"2023103100561364700_bib34","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2023103100561364700_bib35","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2023103100561364700_bib36","doi-asserted-by":"crossref","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"2023103100561364700_bib37","doi-asserted-by":"crossref","first-page":"e064597","DOI":"10.1136\/bmj-2021-064597","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline","volume":"376","author":"Zeng","year":"2022","journal-title":"BMJ"},{"key":"2023103100561364700_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ckj\/sfac221","article-title":"PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations","volume":"16","author":"Casal Moura","year":"2022","journal-title":"Clin Kidney J"},{"key":"2023103100561364700_bib39","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/j.ekir.2022.08.029","article-title":"Practice patterns of induction therapy in severe anti-neutrophil cytoplasmic autoantibody-associated vasculitis","volume":"7","author":"Aqeel","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023103100561364700_bib40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023103100561364700_bib41","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1093\/rheumatology\/keac046","article-title":"Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?","volume":"61","author":"Morel","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023103100561364700_bib42","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023103100561364700_bib43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.06010809","article-title":"Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement\u2014a prospective, open-label pilot trial","volume":"5","author":"Silva","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103100561364700_bib44","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100561364700_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324364","article-title":"Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis","volume":"33","author":"Han","year":"2011","journal-title":"Am J Nephrol"},{"key":"2023103100561364700_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023103100561364700_bib47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103100561364700_bib48","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/ndt\/gfab357","article-title":"Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"37","author":"Berti","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100561364700_bib49","doi-asserted-by":"crossref","first-page":"609924","DOI":"10.3389\/fmed.2021.609924","article-title":"The role of mycophenolate mofetil for the induction of remission in ANCA-associated vasculitis: a meta-analysis","volume":"8","author":"Xiong","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023103100561364700_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"2023103100561364700_bib51","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"2023103100561364700_bib52","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2023103100561364700_bib53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2023103100561364700_bib54","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2023103100561364700_bib55","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","article-title":"Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"van Leeuwen","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023103100561364700_bib56","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ekir.2022.01.1065","article-title":"Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option","volume":"7","author":"Gabilan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023103100561364700_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2023103100561364700_bib58","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2023103100561364700_bib59","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023103100561364700_bib60","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023103100561364700_bib61","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023103100561364700_bib62","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023103100561364700_bib63","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"2023103100561364700_bib64","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","article-title":"Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100561364700_bib65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.06460622","article-title":"Maintenance of remission and risk of relapse in myeloperoxidase positive antineutrophil cytoplasmic antibody-associated vasculitis with kidney involvement","author":"Casal Moura","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023103100561364700_bib66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/qjmed\/hcu043","article-title":"Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011","volume":"107","author":"Romeu","year":"2014","journal-title":"QJM"},{"key":"2023103100561364700_bib67","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"2023103100561364700_bib68","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis\u2014a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2023103100561364700_bib69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2023103100561364700_bib70","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023103100561364700_bib71","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2023103100561364700_bib72","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","article-title":"Development and validation of a renal risk score in ANCA-associated glomerulonephritis","volume":"94","author":"Brix","year":"2018","journal-title":"Kidney Int"},{"key":"2023103100561364700_bib73","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfab250","article-title":"Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody associated vasculitis","volume":"37","author":"Casal Moura","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023103100561364700_bib74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13075-021-02415-z","article-title":"Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis","volume":"23","author":"Yamada","year":"2021","journal-title":"Arthritis Res Ther"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad090\/51272178\/gfad090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/11\/2637\/52660991\/gfad090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/11\/2637\/52660991\/gfad090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:24:59Z","timestamp":1698719099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/11\/2637\/7159733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":74,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,10]]},"published-print":{"date-parts":[[2023,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad090","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,10]]}}}